Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032362 | 0.87 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT | |
| SCHEMBL16090967 | 0.86 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT | |
| SCHEMBL11708665 | 0.85 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2KDM4EHPGDMEN1 | |
| SCHEMBL11708658 | 0.85 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2KDM4EHPGDMEN1 | |
| SCHEMBL16090963 | 0.83 | USP2 (0.45) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT | |
| SCHEMBL26033479 | 0.83 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT | |
| SCHEMBL15499967 | 0.83 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT | |
| SCHEMBL600753 | 0.83 | THRB (0.51) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT | |
| SCHEMBL10409302 | 0.82 | LMNA (0.47) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29541422 | 0.82 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-3366668-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2023-06-21 | — | — | EP | disclosed |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-06-20 | — | — | US | disclosed |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-06-20 | — | — | US | disclosed |
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-08-10 | — | — | US | disclosed |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-11-12 | — | — | US | disclosed |
| US-10596140-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-03-24 | — | — | US | disclosed |
| US-10406133-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-09-10 | — | — | US | disclosed |
| US-20190201367-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-04 | — | — | US | disclosed |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-02-15 | — | — | US | disclosed |
| US-9775823-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-10-03 | — | — | US | disclosed |
| US-9775823-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-10-03 | — | — | US | disclosed |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-04-06 | — | — | US | disclosed |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-04-06 | — | — | US | disclosed |
| US-9505776-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-11-29 | — | — | US | disclosed |
| US-9505776-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-11-29 | — | — | US | disclosed |
| WO-2014152494-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
| US-10406133-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
| US-10596140-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
| US-20190201367-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | ALDH1A1 363/4885SMN1; SMN2 1861/4885KDM4E 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.